December 5, 2019
Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF) shares his perspectives on the data presented today at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego regarding the safety and efficacy of aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of the condition.
December 4, 2019
$50 million global research initiative, funded by Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, among other leading philanthropists, targets resources to speed up development of blood, digital and other biomarkers for early detection of Alzheimer's disease and related dementias.
November 22, 2019
The Bluefield Project to Cure FTD Receives $1.2 Million Award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator
November 4, 2019
CEO Pamela J. Newman of PJN Strategies Honored for Support of Alzheimer’s Research
October 22, 2019
The Alzheimer’s Drug Discovery Foundation is encouraged by today’s announcement from Biogen of its plans to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of Alzheimer’s.
October 17, 2019
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
October 15, 2019
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
September 23, 2019
September 20, 2019
ADDF recognizes Dr. Cummings' significant contributions toward advancing clinical research for Alzheimer's disease
July 15, 2019
The Alzheimer's Drug Discovery Foundation (ADDF) released a new clinical trial analysis report that shows researchers are now developing drugs for various targets associated with aging biology – moving beyond traditional amyloid and tau approaches.
June 11, 2019
The ADDF's Dr. Howard Fillit served as an expert contributor to The Global Council on Brain Health's report on brain health supplements.
May 31, 2019
The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.
May 30, 2019
The first four awards from the first request for proposals total up to approximately $3.5 million.
May 10, 2019
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
May 2, 2019
Hosted by Lindsay Czarniak, the Ninth Annual Great Ladies Luncheon & Fashion Show honored T.J. Oshie of the Washington Capitals and Dr. Michela Gallagher, founder and CEO of AgeneBio.
April 15, 2019
On April 9, the ADDF celebrated its second annual Memories Matter benefit event, which raised over $1 million.
April 2, 2019
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
March 21, 2019
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
March 4, 2019
The Second Annual Hope on the Horizon Palm Beach Luncheon honoring Marcia Gay Harden raised over $350,000 for the ADDF.
February 19, 2019
Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation announce a joint request for proposals for the 2019 ADDF-Harrington Scholar Award.
January 11, 2019
The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.
January 9, 2019
A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.
January 3, 2019
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
November 5, 2018
The Alzheimer's Drug Discovery Foundation's Ninth Annual Fall Symposium & Luncheon raised a record-breaking total of over $1.6 million.
October 23, 2018
The Alzheimer's Drug Discovery Foundation is saddened to hear the news that former Supreme Court Justice Sandra Day O'Connor has been diagnosed with the beginning stages of dementia.
September 21, 2018
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
September 17, 2018
Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.
September 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
July 17, 2018
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
July 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
May 10, 2018
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
May 7, 2018
Fabrizio Freda, President and CEO of The Estée Lauder Companies, was honored at our Annual Connoisseur’s Dinner in New York City. The event raised $2.6 million for Alzheimer’s research.
May 1, 2018
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
April 24, 2018
On Wednesday, April 18, the ADDF raised over $650,000 for innovative research at our Eighth Annual Great Ladies Luncheon & Fashion Show.
April 12, 2018
Our inaugural Memories Matter benefit raised $1.2 million for Alzheimer's drug research.
March 28, 2018
Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.
March 16, 2018
On Tuesday, March 13, the Alzheimer’s Drug Discovery Foundation (ADDF) honored Kim Campbell for her charitable work at our Premiere Women’s Luncheon at Club Colette in Palm Beach.
March 13, 2018
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
February 20, 2018
The Alzheimer’s Drug Discovery Foundation is once again an Official Charity Partner of the 2018 TCS New York City Marathon, which takes place on Sunday, November 4, 2018.
January 8, 2018
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
November 14, 2017
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
November 1, 2017
Closing in on a Cure: 2017 Alzheimer’s Clinical Trials Report surveys the 126 drugs in clinical development for Alzheimer’s disease—20% of which received support from the Alzheimer’s Drug Discovery Foundation.
October 30, 2017
Sharon Sager from UBS received The Charles Evans Award at our Eighth Annual Fall Symposium & Luncheon. The event raised over $1.2 million.
October 24, 2017
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
October 3, 2017
The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.
September 14, 2017
Dr. Brinton has pioneered a promising neurogenesis therapy for Alzheimer’s disease.
September 13, 2017
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
September 5, 2017
The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.
July 11, 2017
The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.
June 29, 2017
The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.
June 7, 2017
New “CRO Finder” Connects Scientists with Specialized Resources
May 15, 2017
We announce 10 new grants totaling over $2.6 million to drive promising new approaches to treating and diagnosing Alzheimer’s and related dementias.
May 11, 2017
11th annual gala raises $2.5 million for lifesaving Alzheimer's treatments
April 27, 2017
We raised over $350,000 for life-saving research at our Seventh Annual Great Ladies Luncheon & Fashion Show in Washington, DC, which honored author Sally for her work in the fight against Alzheimer's.
April 24, 2017
A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.
April 20, 2017
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
April 13, 2017
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
March 7, 2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
February 3, 2017
We have been chosen as Official Charity Partner of the TCS New York City Marathon for the third year. The race will take place on Sunday, November 5, 2017.
January 18, 2017
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
January 10, 2017
Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.
January 9, 2017
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
November 15, 2016
On November 14, Donald Newhouse received The Charles Evans Award from the ADDF at our Seventh Annual Fall Symposium & Luncheon at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.
November 8, 2016
The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.
October 27, 2016
The streamlined site separates fact from fiction and empowers people to make smarter choices for their brain health.
September 29, 2016
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
September 22, 2016
Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.
September 21, 2016
With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.
September 13, 2016
Dr. Watterson has identified a number of new classes of Central Nervous System drugs.
September 12, 2016
The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias.
August 24, 2016
With better evidence, routine medical decisions could help prevent dementia.
July 7, 2016
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
May 13, 2016
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.
May 10, 2016
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
April 29, 2016
Annual Gala Raised over $3.25 million for Alzheimer’s Treatments
April 14, 2016
Sixth Annual Great Ladies Luncheon & Fashion Show most successful in event's history
March 9, 2016
For the second year in a row, the ADDF has been chosen as an Official Charity Partner of the 2016 TCS New York City Marathon. The race will take place on Sunday, November 6, 2016.
February 25, 2016
Grants awarded in the first two months of 2016 support researchers in the U.S. and Middle East pursuing drug programs, prevention studies, and research to accelerate clinical trials.
February 2, 2016
The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s.
January 12, 2016
We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs.
January 5, 2016
Funded Researchers are pursuing diverse targets to treat Alzheimer's disease.
December 29, 2015
At the December joint meeting, the ADDF Boards of Governors and Overseers welcomed seven new members.
November 10, 2015
On November 9, Margaret and Daniel Loeb received The Charles Evans Award at our Annual Fall Symposium & Luncheon, which raised more than $1 million.
November 4, 2015
AlzeCure Foundation announced today that it has been awarded a grant from the ADDF to support the further development of its small molecule neurorestorative project.
September 16, 2015
Dr. Longo's pioneering approach may soon lead to new disease modifying drugs.
August 26, 2015
Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.
August 24, 2015
The ADDF is featured in an episode of Innovations with Ed Begley Jr. on the Discovery Channel.
August 12, 2015
Melvin R. Goodes Prize supports innovative projects by top researchers while honoring the legacy of the former Warner-Lambert CEO.
August 6, 2015
Jarman Wines, a winery in Carmel Valley, will introduce two premium varietals to benefit the ADDF and to honor the matriarch of the family whose name graces the wines created for her.
July 30, 2015
Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.
May 4, 2015
On April 27, 2015, Susan Stroman hosted the ADDF's Ninth Annual Connoisseur’s Dinner, which raised more than $2.8 million for Alzheimer's drug discovery and development.
April 17, 2015
Renowned journalist and NPR host Diane Rehm spoke about the need to increase support for drug discovery for Alzheimer's at the ADDF's Annual Great Ladies Luncheon & Fashion Show.
April 9, 2015
Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.
March 17, 2015
The ADDF awarded $1 million to GliaCure to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer's disease.
March 3, 2015
The ADDF is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon.
February 11, 2015
The ADDF and Pfizer’s Centers for Therapeutic Innovation are collaborating to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.
January 28, 2015
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
December 18, 2014
The ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer's disease by targeting inflammation.
December 11, 2014
The ADDF and the Alzheimer's Society UK announced new funding to explore the possibility of using tadalafil, a commonly prescribed drug which treats erectile dysfunction, as the next treatment for dementia.
November 4, 2014
Former model and restaurateur B. Smith was honored by the ADDF at its Fifth Annual Fall Symposium & Luncheon for raising public awareness and critical funds to combat Alzheimer's disease.
September 10, 2014
The ADDF and OnDeckBiotech announced the relaunch of ADDF ACCESS as a new and improved platform to connect scientists with a virtual network of contract research organizations.
June 26, 2014
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.
June 26, 2014
The ADDF and OnDeckBiotech announced a strategic partnership to provide a new platform technology for ADDF ACCESS. Utilizing OnDeckBiotech's technology, ADDF ACCESS will increase the efficiency of contracting drug development services.
June 9, 2014
Researchers from The Ohio State and Emory Universities will be the first recipients of drug discovery funding and innovation support from a new partnership between the ADDF and Harrington Discovery Institute.
May 2, 2014
The ADDF raised more than $1.1 million at its Eighth Annual Connoisseur's Dinner to go to Jeffrey Cummings, MD in support of a clinical trial for a repurposed drug for treating Alzheimer's disease.
April 23, 2014
The ADDF launched Cognitive Vitality, an online resource that provides overviews and analyses of dementia prevention strategies.
March 24, 2014
In partnership with the ADDF, the Alzheimer's Disease and Dementia Initiative at the New York Academy of Sciences has awarded a grant to Blaine Roberts, PhD, at The Florey Institute of Neuroscience and Mental Health.
March 14, 2014
The ADDF and the Children's Tumor Foundation announced a partnership to provide CTF's community of neurofibromatosis researchers access to the ADDF ACCESS program.
March 11, 2014
The ADDF and The Association for Frontotemporal Degeneration announced the recipients of their seventh annual partnership awards program to accelerate drug discovery for frontotemporal degeneration.
February 27, 2014
The ADDF and the Foundation for Mitochondrial Medicine awarded $200,000 to James Bennett, M.D., Ph.D. to further research gene therapy of mitochondrial protein in mice with experimental Alzheimer's disease.
January 28, 2014
The ADDF and The W. Garfield Weston Foundation announced a funding collaboration to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer's disease progression.
January 24, 2014
The ADDF and the Alzheimer’s Society (UK) announced a new partnership that intends to fund projects up to $1.5 million each focused on drug repurposing.
November 6, 2013
The ADDF expanded its ACCESS program to provide a virtual network of drug discovery experts and contract research organizations that can expedite the development of therapies for neurodegenerative diseases.
October 24, 2013
Chris Johnson, son of legendary New York Giants Running Back Ron Johnson, has taken up the cause to find a cure for Alzheimer's disease.
October 24, 2013
The ADDF and the Harrington Discovery Institute's partnership leverages their combined expertise and resources to advance promising Alzheimer's drug discovery projects.
August 26, 2013
London-based luxury designer Patricia Gomez-Garcia created this limited edition item in support of the ADDF.
August 20, 2013
The ADDF presents its annual fall conference on Alzheimer's drug discovery on September 9-10, 2013 in Jersey City, New Jersey.
July 1, 2013
The ADDF launched the ADDF ACCESS program to give academic and small biotechnology communities online access to industry standard preclinical drug discovery and development services.
June 12, 2013
The ADDF announced that it has awarded follow-on funding to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain.
April 24, 2013
The ADDF and BrightFocus Foundation announced a funding collaboration to support a Phase I clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's.
March 25, 2013
The ADDF and the Lewy Body Dementia Association awarded two grants of $100,000 each to support research on developing biomarkers for dementia with Lewy bodies.
March 6, 2013
The ADDF has awarded $205,260 in funding to CohBar Inc. to develop a mitochondrial peptide, which has been shown to have neuroprotective effects.
February 28, 2013
The Alzheimer's Drug Discovery Foundation, Beyond Batten Disease Foundation, and the National Multiple Sclerosis Society announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative.
February 5, 2013
Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.
April 6, 2012
The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.